Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143520 · ClinicalTrials.gov registry record · Phase 2
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 441
- Enrollment target
NCT00143520 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 441 participants.
The verdict
NCT00143520, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 441 participants
- Enrollment target
Study Summary
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment group for comparison.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Rivoglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2004-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143520
The ClinicalTrials.gov registry entry for NCT00143520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00143520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143520 about?
NCT00143520 is a clinical study titled "Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes". This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a placebo and active treatment...
What is the current status of trial NCT00143520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 441 participants. The study started on 2004-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00143520?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Rivoglitazone (DRUG).
Who is sponsoring clinical trial NCT00143520?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.